Evidence types
Phase 1 clinical trial articles covering early human safety, dosing, and first-in-human treatment research relevant to IBD.
19 articles
an investigational oral drug (PALI-2108) being developed specifically for UC and Crohn’s disease, reporting favorable Phase 1 safety and early activity and noting upcoming Phase 2 readouts. For people following new...
A new Phase 2 Crohn’s trial is planned for Q3 2026 of an investigational DR3‑blocking antibody (SL‑325), which could become a novel treatment approach if later trials show benefit. The report is an investor roundup, so...
Fibrosis and strictures (fibrostenotic disease) are important unmet problems in Crohn’s disease with limited medical options. An investigational drug that targets PDE4 locally could potentially offer a new approach if...
Cure8 found this source from tipranks.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. Open the original article for the...
This study tests a live Faecalibacterium prausnitzii probiotic (EXL01) as a way to prolong steroid-induced remission in Crohn’s disease, a potential new strategy to reduce relapses and steroid exposure.
Early clinical data suggest PALI-2108 may affect both inflammation and fibrosis in Crohn’s disease and shows biomarker changes (like fecal calprotectin) that could matter to people monitoring disease activity.
Cure8 could only read part of this source from marketscreener.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Stricture, and Research and clinical trials.
This is the first reported organoid-based intestinal regenerative therapy entering clinical trials, which could offer a new approach for Crohn’s patients whose ulcers don’t heal with current treatments. Early-stage...
Based on the title and source metadata, this appears to be a clinical trial phase 1 related to Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. The original article is from msn.com.
Cure8 found this source from tipranks.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. Open the original article for the...
Perianal fistulas are a serious, hard-to-treat complication of Crohn disease. Fast Track status may speed development of a new implantable stem cell therapy that aims to close fistulas and promote local healing. Ongoing...
Patients and clinicians following new, non‑immunosuppressive approaches to UC may be interested because MB310 is an oral live‑biotherapeutic designed to induce remission and is entering clinical testing.
Cure8 found this source from businesswire.com, but the page could not be read reliably yet. It is tagged for Research and clinical trials. Open the original article for the full details.
This reports a potential new way to extend remission after exclusive enteral nutrition by combining diet with fecal microbiome transfer—an approach that targets the gut microbiome rather than adding drugs. If effective,...
This study tests whether a ‘microbiome reboot’ — using exclusive enteral nutrition followed by fecal microbiome transfer — can make the beneficial microbiome changes last longer and help keep Crohn’s disease in...
This article reports the start of a first-in-human trial testing extracellular vesicles as a new regenerative treatment for complex perianal fistulas in Crohn's disease, a hard-to-treat complication with limited options.
If successful, validated biomarkers and a blood risk score could allow clinicians to identify people at high risk of developing Crohn's disease and eventually test interventions to prevent symptoms. Prevention-focused...
Cure8 found this source from pharmaceutical-technology.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. Open the original...
This notes a new oral investigational drug (Amelenodor/NX-13) in Phase I for Crohn’s and ulcerative colitis and highlights industry predictions about its chances of advancing. People with IBD may want to know about...
